Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Bristol-Myers Rises After FDA Approves Blood Thinner Eliquis


The anti-clotting drug developed with Pfizer is seen as a potential blockbuster drug. The product was approved three months earlier than expected.

MINYANVILLE ORIGINAL Shares of Bristol-Myers Squibb (NYSE:BMY) are rising after the drug maker won US approval for Eliquis, its blood-thinning treatment aimed at preventing strokes and serious blood clots.

Bristol-Myers and development partner Pfizer (NYSE:PFE) got word of the approval Friday afternoon, almost three months earlier than a deadline set by the Food and Drug Administration. The FDA rejected the drug last June, saying the companies needed to provide more information to show the medicine works and is safe.

Eliquis is an alternative to warfarin, which has been used for decades. Other companies, including Johnson & Johnson (NYSE:JNJ) and Boehringer Ingelheim, sell their own new warfarin replacements. J&J sells the Bayer-licensed drug Xarelto and German-based Boehringer markets Pradaxa.

"We continue to believe Eliquis is well positioned to be the leader in the warfarin-replacement market," Leerink Swann analyst Seamus Fernandez says in a note Monday morning.

Both Bristol-Myers and Pfizer need big, new drugs to replace older treatments that now face generic competition.

Shares of Bristol-Myers rose 2% to $32.40 in morning trading Monday. The stock declined 8% in 2012. Shares of Pfizer, which is more than three times the market cap of Bristol-Myers, fell less than 1% to $24.85. Pfizer's stock rose 15% in 2012.

(See also: Keep an Eye on These Five New Drugs in the First Quarter of 2013.)

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos